Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
PDX1328 AZD7762
10.0
CHK1/2
Cell cycle
 -0.8228 0.55548
MDA-MB-453 Torin2
1.0
mTOR/ATM/ATR
PI3K/mTOR
 -0.8141 0.71155
HCC1500 Cediranib
10.0
VEGFR/cKIT
RTK
 -0.8084 0.60186
HCC1500 Topotecan
3.1623
Topo I
Chemotherapy
 -0.8011 0.44379
MDA-MB-361 Alpelisib
10.0
PI3Ka
PI3K/mTOR
 -0.7994 0.64634
MDA-MB-134-VI Topotecan
3.1623
Topo I
Chemotherapy
 -0.7896 0.43857
MDA-MB-361 Torin2
0.31623
mTOR/ATM/ATR
PI3K/mTOR
 -0.7864 0.62347
MDA-MB-134-VI INK-128
0.31623
mTORC1/2
PI3K/mTOR
 -0.7860 0.43333
MDA-MB-157 AZD7762
10.0
CHK1/2
Cell cycle
 -0.7858 0.69727
HCC1419 Topotecan
10.0
Topo I
Chemotherapy
 -0.7857 0.67086
HCC1500 Topotecan
1.0
Topo I
Chemotherapy
 -0.7846 0.43474
HCC70 Doxorubicin
3.1623
Chemo
Chemotherapy
 -0.7794 0.71318
PDX1328 Doxorubicin
3.1623
Chemo
Chemotherapy
 -0.7789 0.65064
MDA-MB-134-VI Torin2
0.1
mTOR/ATM/ATR
PI3K/mTOR
 -0.7768 0.43263
MDA-MB-157 Doxorubicin
3.1623
Chemo
Chemotherapy
 -0.7766 0.77243
MDA-MB-361 Vorinostat
3.1623
HDAC
Misc
 -0.7719 0.59745
MDA-MB-134-VI Luminespib
1.0
HSP90
Misc
 -0.7660 0.42401
HCC1500 Topotecan
10.0
Topo I
Chemotherapy
 -0.7655 0.40218
SUM1315MO2 Ceritinib
10.0
ALK
RTK
 -0.7650 0.67576
MDA-MB-453 Abemaciclib
10.0
CDK4/6
Cell cycle
 -0.7647 0.62806
MDA-MB-361 Topotecan
10.0
Topo I
Chemotherapy
 -0.7622 0.38237
MDA-MB-134-VI INK-128
0.1
mTORC1/2
PI3K/mTOR
 -0.7575 0.38820
PDX1328 Abemaciclib
10.0
CDK4/6
Cell cycle
 -0.7514 0.53932
MDA-MB-468 Ceritinib
10.0
ALK
RTK
 -0.7415 0.83751
HCC1428 Doxorubicin
3.1623
Chemo
Chemotherapy
 -0.7396 0.82745